Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 5/20 | 0.66 |
| ▸ | PDE1A | P54750 | 5/20 | 0.66 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.66 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.66 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6372442 | 0.89 | PDE1A (0.51) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367437 | 0.87 | PDE9A (0.49) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366324 | 0.86 | PDE9A (0.48) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366835 | 0.86 | PDE9A (0.74) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6368321 | 0.86 | PDE9A (0.59) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6418301 | 0.84 | PDE9A (0.64) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366619 | 0.84 | DPYD (0.46) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6373774 | 0.81 | AR (0.46) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6368296 | 0.81 | MEN1 (0.52) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6365848 | 0.81 | LMNA (0.49) | PDE9APDE1APDE1BPDE1CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE9A 3/4885PDE1A 46/4885PDE1B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.